We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Solid Biosciences Inc (SLDB) USD0.001

Sell:$8.73 Buy:$8.77 Change: $0.44 (4.83%)
NASDAQ:0.10%
Market closed |  Prices as at close on 24 April 2024 | Switch to live prices |
Sell:$8.73
Buy:$8.77
Change: $0.44 (4.83%)
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
Market closed |  Prices as at close on 24 April 2024 | Switch to live prices |
Sell:$8.73
Buy:$8.77
Change: $0.44 (4.83%)
Market closed |  Prices as at close on 24 April 2024 | Switch to live prices |
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Solid Biosciences Inc. is a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases. The Company is focused on advancing a portfolio of gene therapy candidates including SGT-003 for the treatment of Duchenne muscular dystrophy, SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia, AVB-401 for the treatment of BAG3-mediated dilated cardiomyopathy, and additional assets for the treatment of fatal cardiac diseases. The Company also has two cardiac pipeline gene transfer programs, SGT-601 for TNNT2 DCM and SGT-701 for RBM20 DCM, that are both in early preclinical development. It also has a neuromuscular gene transfer program for the treatment of Friedreich's ataxia. In addition to its gene transfer candidates, the Company has development programs focusing on platform technologies, including novel capsid libraries and dual gene expression, a technology that allows it to package multiple transgenes into one capsid.

Contact details

Address:
500 RUTHERFORD AVENUE, 3RD FLOOR
CHARLESTOWN
02129
United States
Telephone:
+1 (617) 3374680
Website:
https://www.solidbio.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
SLDB
ISIN:
US83422E2046
Market cap:
$343.97 million
Shares in issue:
37.76 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
NASDAQ Comb. Composite

Key personnel

  • Ian Smith
    Executive Chairman of the Board
  • Alexander Cumbo
    President, Chief Executive Officer, Director
  • Ilan Ganot
    Co-Founder, Director
  • Kevin Tan
    Chief Financial Officer, Treasurer
  • Paul Herzich
    Chief Technology Officer
  • David Howton
    Chief Administrative Officer and Secretary
  • Gabriel Brooks
    Chief Medical Officer
  • Jessie Hanrahan
    Chief Regulatory Officer
  • Jennifer Marlowe
    Chief Scientific Officer - Friedreich’s Ataxia and Cardiac Pipeline

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now

Options

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.